Table 3

British Columbia Randomized Radiation trial, 2005 update

Hazard ratio
 95% confidence interval
DFS
     All patients
 0.63
 0.47 to 0.83
     N1 to N3
 0.64
 0.42 to 0.97
     N4+
 0.59
 0.38 to 0.91
SysDFS
     All patients
 0.66
 0.49 to 0.88
     N1 to N3
 0.68
 0.45 to 1.04
     N4+
 0.63
 0.41 to 0.97
Overall survival
     All patients
 0.73
 0.55 to 0.98
     N1 to N3
 0.76
 0.50 to 1.15
     N4+
 0.63
 0.41 to 0.97

Cyclophosphamide methotrexate, 5-fluoracil + radiation versus cyclophosphamide methotrexate, 5-fluoracil alone, including all patients and involving patients with one to three axillary nodes involved (N1 to N3) and patients with four or more axillary nodes involved (N4+). DFS, first event breast cancer recurrence (or any death); SysDFS, DFS with systemic recurrence as a first event. Adapted from Ragaz and colleagues [12].

Ragaz Breast Cancer Research 2009 11(Suppl 3):S14   doi:10.1186/bcr2433